Cardlytics (NASDAQ: CDLX) reported Q4 EPS of ($0.05), $0.02 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $67.1 million versus the consensus estimate of $60.89 million.

Fourth Quarter 2020 Financial Results

• Total revenue was $67.1 million, a decrease of (3.2)%, compared to $69.3 million in the fourth quarter of 2019.
• Net loss attributable to common stockholders was $(6.8) million, or $(0.24) per diluted share, based on 27.7 million weighted-average common shares outstanding, compared to a net income attributable to common stockholders of $3.4 million, or $0.12 per diluted share, based on 26.1 million weighted-average common shares outstanding in the fourth quarter of 2019.
• Non-GAAP net loss was $(1.5) million, or $(0.05) per diluted share, based on 27.7 million weighted-average common shares outstanding, compared to a non-GAAP net income of $5.2 million, or $0.18 per diluted share, based on 28.1 million weighted-average common shares outstanding in the fourth quarter of 2019.
• Billings, a non-GAAP metric, was $94.0 million, a decrease of (6.9)%, compared to $100.9 million in the fourth quarter of 2019.
• Adjusted contribution, a non-GAAP metric, was $29.7 million, a decrease of (4.4)%, compared to $31.0 million in the fourth quarter of 2019.
• Adjusted EBITDA, a non-GAAP metric, was a gain of $4.5 million, a decrease of $(2.4) million, compared to a gain of $6.9 million in the fourth quarter of 2019.

“We are pleased to announce strong fourth quarter results that exceeded our prior guidance for both revenue and billings,” said Lynne Laube, CEO & Co-Founder of Cardlytics. “As previously announced, we look forward to welcoming Dosh’s talented team and partners to Cardlytics. Dosh’s technology is extremely complementary to the long-term financial institution integrations and substantial scale we’ve built over the past thirteen years.”

“As expected, we continued to see month over month increases in billings and revenue through the end of the year,” said Andy Christiansen, CFO of Cardlytics. “We look forward to returning to growth in 2021 and see many exciting organic and inorganic investment opportunities to support long-term growth in shareholder value.”

GUIDANCE:

Cardlytics sees Q1 2021 revenue of $47-53 million, versus the consensus of $50.07 million.

Cardlytics sees FY2021 revenue of $250-275 million, versus the consensus of $255.59 million.

For earnings history and earnings-related data on Cardlytics (CDLX) click here.